Published in Virology on May 01, 1992
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A (1992) 4.58
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Poxvirus tropism. Nat Rev Microbiol (2005) 3.07
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Nipah virus: vaccination and passive protection studies in a hamster model. J Virol (2004) 2.09
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol (2010) 1.96
Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J Virol (2004) 1.96
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A (1998) 1.93
Japanese encephalitis-a pathological and clinical perspective. PLoS Negl Trop Dis (2009) 1.82
Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc Natl Acad Sci U S A (1995) 1.80
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68
Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A (1999) 1.63
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol (2004) 1.59
Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol (1996) 1.58
The genome of canarypox virus. J Virol (2004) 1.56
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood (2005) 1.54
Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist. J Virol (2006) 1.53
Double-stranded RNA binding by human cytomegalovirus pTRS1. J Virol (2005) 1.44
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44
Essential role for either TRS1 or IRS1 in human cytomegalovirus replication. J Virol (2009) 1.37
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35
Identification from diverse mammalian poxviruses of host-range regulatory genes functioning equivalently to vaccinia virus C7L. Virology (2007) 1.29
Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J Virol (2007) 1.28
Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol (2006) 1.26
Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol (2009) 1.24
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun (1996) 1.20
Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol (2005) 1.16
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15
A global approach to HIV-1 vaccine development. Immunol Rev (2013) 1.14
Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J Virol (2001) 1.14
Complementation of vaccinia virus lacking the double-stranded RNA-binding protein gene E3L by human cytomegalovirus. J Virol (2002) 1.13
Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol (2002) 1.11
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J Virol (1994) 1.09
A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J (2010) 1.07
Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes. J Virol (2004) 1.06
Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies. Virology (2008) 1.05
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J Virol (2004) 1.05
Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun (1996) 1.03
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine (2007) 1.02
Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol (1993) 1.01
Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol (2008) 1.01
Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J Virol (2008) 1.01
Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine (2008) 0.99
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A (2008) 0.98
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines (2011) 0.98
Functional analysis of N-linked glycosylation mutants of the measles virus fusion protein synthesized by recombinant vaccinia virus vectors. J Virol (1994) 0.96
Adaptive gene amplification as an intermediate step in the expansion of virus host range. PLoS Pathog (2014) 0.95
Smallpox vaccines for biodefense. Vaccine (2009) 0.92
The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol (2013) 0.92
Non-replicating expression vectors: applications in vaccine development and gene therapy. Epidemiol Infect (1996) 0.92
Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors. J Virol (2007) 0.92
Species specificity of protein kinase r antagonism by cytomegalovirus TRS1 genes. J Virol (2012) 0.91
Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord (2005) 0.90
A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum Vaccin Immunother (2012) 0.90
Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo. Proc Natl Acad Sci U S A (2005) 0.89
Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression. J Virol (1999) 0.88
Nonhuman primate models for HIV/AIDS vaccine development. Curr Protoc Immunol (2013) 0.88
Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J Gen Virol (2007) 0.88
Reflections on the early development of poxvirus vectors. Vaccine (2013) 0.88
Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo. J Virol (2011) 0.87
Virus-vectored influenza virus vaccines. Viruses (2014) 0.86
Avipoxviruses: infection biology and their use as vaccine vectors. Virol J (2011) 0.86
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. J Virol (2015) 0.83
OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses. Immunol Rev (2011) 0.82
Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses. J Virol (2014) 0.82
From actually toxic to highly specific--novel drugs against poxviruses. Virol J (2007) 0.82
Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. J Virol (2000) 0.81
A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS One (2012) 0.80
Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells. Vaccine (2009) 0.79
Viral vector-based influenza vaccines. Hum Vaccin Immunother (2016) 0.79
Retracted Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys. J Virol (2003) 0.78
Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000. Clin Vaccine Immunol (2014) 0.78
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol (2016) 0.78
Serological responses in humans to the smallpox vaccine LC16m8. J Gen Virol (2011) 0.77
Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes. PLoS One (2012) 0.77
Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus). J Virol (2001) 0.77
Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus. Can J Vet Res (1996) 0.76
Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. Vaccine (2013) 0.76
Protective properties of vaccinia virus-based vaccines: skin scarification promotes a nonspecific immune response that protects against orthopoxvirus disease. J Virol (2014) 0.76
Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity. J Virol (2017) 0.75
The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus. Vaccine (2011) 0.75
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
Behavioral disinhibition and the development of substance-use disorders: findings from the Minnesota Twin Family Study. Dev Psychopathol (1999) 5.90
Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol (1989) 5.48
Diagnosis and management of aortic dissection. Eur Heart J (2001) 5.39
Structure and replication of the genome of the hepatitis delta virus. Proc Natl Acad Sci U S A (1986) 5.23
An investigation of traveller's diarrhoea. Lancet (1970) 4.99
Molecular cloning of hepatitis delta virus RNA from an infected woodchuck liver: sequence, structure, and applications. J Virol (1988) 4.96
Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol (1988) 4.59
Herpes simplex virus 1 mutant deleted in the alpha 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice. J Virol (1985) 4.17
A specific base transition occurs on replicating hepatitis delta virus RNA. J Virol (1990) 4.05
Characterization of self-cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol (1988) 4.05
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med (1994) 3.72
Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol (1990) 3.57
Inhibition of interferon action by actinomycin. Biochem Biophys Res Commun (1964) 3.55
A study of Escherichia coli isolated from chronic urinary infection. J Med Microbiol (1969) 3.32
Template switching by reverse transcriptase during DNA synthesis. J Virol (1990) 2.98
Using nurses for preventive activities with computer assisted follow up: a randomised controlled trial. BMJ (1989) 2.95
Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study. Lancet (1977) 2.90
Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res (2001) 2.90
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation (2009) 2.85
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Immunization against Diphtheria with Alum-precipitated Toxoid-II. Br Med J (1942) 2.77
A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS (1999) 2.75
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Psychotic illness following 'mabi bark tea' consumption. Br J Psychiatry (1992) 2.72
Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol (1999) 2.65
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J (2004) 2.63
Comparison of influenza serological techniques by international collaborative study. Vaccine (1994) 2.55
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci U S A (1997) 2.54
MutS mediates heteroduplex loop formation by a translocation mechanism. EMBO J (1997) 2.52
A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol Cell Biol (1994) 2.42
Transient Induction of Phenylalanine Ammonia-Lyase and 4-Coumarate: CoA Ligase mRNAs in Potato Leaves Infected with Virulent or Avirulent Races of Phytophthora infestans. Plant Physiol (1987) 2.36
Replication of human hepatitis delta virus in primary cultures of woodchuck hepatocytes. J Virol (1987) 2.36
Assembly of hepatitis delta virus particles. J Virol (1992) 2.36
Structural asymmetries in the human brain: a voxel-based statistical analysis of 142 MRI scans. Cereb Cortex (2001) 2.32
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
Rapid immune response to influenza vaccination. Lancet (1993) 2.09
Roles of estrogen receptor-alpha gene expression in reproduction-related behaviors in female mice. Endocrinology (1998) 2.05
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen. J Virol (1990) 2.03
Vaccinia virus host range genes. Virology (1990) 2.02
Hereditary haemorrhagic telangiectasia, an Australian cohort: clinical and investigative features. Intern Med J (2014) 1.98
Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis. J Virol (1992) 1.94
Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg (1998) 1.91
Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther (1992) 1.88
The stability and properties of bimolecular lipid leaflets in aqueous solutions. J Theor Biol (1963) 1.80
Self-ligating RNA sequences on the antigenome of human hepatitis delta virus. J Virol (1989) 1.78
Ketamine sedation for children in the emergency department. Emerg Med (Fremantle) (2001) 1.78
Cloned hepatitis delta virus cDNA is infectious in the chimpanzee. J Virol (1989) 1.75
Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail (1999) 1.75
A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol (2001) 1.73
Outbreak of infantile gastro-enteritis caused by Escherichia coli O114. Arch Dis Child (1970) 1.71
The antigen of hepatitis delta virus: examination of in vitro RNA-binding specificity. J Virol (1991) 1.70
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology (2010) 1.66
Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med (1999) 1.65
Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur J Vasc Endovasc Surg (1996) 1.65
Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol (2001) 1.64
Controlling deaths from volatile substance abuse in under 18s: the effects of legislation. BMJ (1992) 1.63
The variation of capacitance and conductance of bimolecular lipid membranes with area. J Theor Biol (1965) 1.62
The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates. J Virol (1993) 1.62
Recombinant vaccinia virus: immunization against multiple pathogens. Science (1985) 1.60
Children with unexplained chronic pain: substantial impairment in everyday life. Arch Dis Child (2005) 1.60
Acute lobar atelectasis. A comparison of two chest physiotherapy regimens. Chest (1990) 1.59
Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol (1999) 1.59
Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA (1984) 1.58
Avoided and avoidable risks of cancer. Carcinogenesis (1997) 1.58
Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem (2000) 1.58
Modifications of testosterone-dependent behaviors by estrogen receptor-alpha gene disruption in male mice. Endocrinology (1998) 1.57
Polar group orientation and the electrical properties of lecithin bimolecular leaflets. J Theor Biol (1965) 1.57
Combined Active and Passive Immunization against Diphtheria: II. Control of Epidemics in the Field. Br Med J (1941) 1.57
Ribonucleoprotein complexes of hepatitis delta virus. J Virol (1993) 1.56
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56
Specificities involved in the initiation of retroviral plus-strand DNA. J Virol (1990) 1.55
Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Epilepsia (1996) 1.54
Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis (1991) 1.53
Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes (1996) 1.53
The influence of lipid composition and of some adsorbed proteins on the capacitance of black hydrocarbon membranes. J Theor Biol (1965) 1.51
Spin waves and revised crystal structure of honeycomb iridate Na2IrO3. Phys Rev Lett (2012) 1.49
Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum (1984) 1.49
Editing on the genomic RNA of human hepatitis delta virus. J Virol (1992) 1.48
A cluster randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of classroom-based cognitive-behavioural therapy (CBT) in reducing symptoms of depression in high-risk adolescents. Health Technol Assess (2013) 1.46
Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol (2000) 1.45
Canal adaptation and coronal leakage: lateral condensation compared to Thermafil. J Am Dent Assoc (1995) 1.45
Bier's block--the experience of Australian emergency departments. Med J Aust (1994) 1.44
Reprinted article "Factors associated with early failure of arteriovenous fistulae for haemodialysis access". Eur J Vasc Endovasc Surg (2011) 1.44
Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem (1997) 1.42
Computerized literature searching in a teaching family practice center. Fam Pract Res J (1991) 1.42
The complete DNA sequence and the genetic organization of the short unique region (US) of the bovine herpesvirus type 1 (ST strain). Virology (1994) 1.42
Circumstances of sexual and physical victimization of black psychiatric outpatients. J Natl Med Assoc (1989) 1.41